韩国类风湿关节炎靶向治疗患者中Boolean 2.0缓解标准与生活质量预测的验证
研究纳入506例起始JAK抑制剂或生物制剂治疗的韩国类风湿关节炎患者,414例完成48周随访,验证Boolean 2.0将患者总体评估阈值修订为2 cm后与基于指数的缓解标准的一致性及对生活质量结局的预测效度。结果显示Boolean 2.0与DAS28-ESR缓解的一致性优于Boolean 1.0(κ=0.50 vs 0.39),但与CDAI(κ=0.75 vs 0.48)和SDAI(κ=0.76 vs 0.64)的一致性更弱,且对HAQ-DI≤0.5和EQ-5D=1的阳性预测值低于Boolean 1.0。结论认为Boolean 2.0虽改善与DAS28-ESR的一致性,但未增强对长期功能或生活质量结局的预测,其更宽的缓解定义在临床实践中需谨慎解读。
要点
- Boolean 2.0与DAS28-ESR缓解一致性优于Boolean 1.0(κ=0.50 vs 0.39)。
- Boolean 2.0与CDAI及SDAI一致性均弱于Boolean 1.0(κ=0.75 vs 0.48;κ=0.76 vs 0.64)。
- Boolean 1.0对HAQ-DI≤0.5(0.90 vs 0.82)和EQ-5D=1(0.38 vs 0.30)的阳性预测值高于Boolean 2.0。
核心结论
- Boolean 2.0虽改善与DAS28-ESR缓解的一致性,但未增强对长期功能或生活质量结局的预测,其更宽的缓解定义在临床实践中需谨慎解读。
研究设计与样本
- 多中心前瞻性队列研究,纳入506例起始Janus激酶抑制剂或生物改善病情抗风湿药治疗的类风湿关节炎患者,414例完成48周随访。
主要发现
- Boolean 2.0与DAS28-ESR缓解的一致性κ=0.50,高于Boolean 1.0的κ=0.39。
- Boolean 2.0与CDAI缓解的一致性κ=0.75,低于Boolean 1.0的κ=0.48。
- Boolean 2.0与SDAI缓解的一致性κ=0.76,低于Boolean 1.0的κ=0.64。
- Boolean 1.0对HAQ-DI≤0.5的阳性预测值为0.90,高于Boolean 2.0的0.82。
- Boolean 1.0对EQ-5D=1的阳性预测值为0.38,高于Boolean 2.0的0.30。
关键数值与推荐
- Boolean 2.0将患者总体评估阈值修订为2 cm,与DAS28-ESR、CDAI、SDAI缓解标准的一致性κ分别为0.50、0.75、0.76。
- Boolean 1.0与DAS28-ESR、CDAI、SDAI缓解标准的一致性κ分别为0.39、0.48、0.64。
- Boolean 1.0对HAQ-DI≤0.5和EQ-5D=1的阳性预测值分别为0.90和0.38,Boolean 2.0分别为0.82和0.30。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate the revised patient global assessment (PtGA) threshold of 2 cm in the Boolean 2.0 remission definition by assessing its agreement with index-based remission criteria and its predictive validity for quality of life (QoL) outcomes, compared with Boolean 1.0, in Korean patients with rheumatoid arthritis (RA) receiving targeted therapy. METHODS: Data from a multicentre prospective cohort of patients with RA initiating treatment with Janus kinase inhibitors or biologic disease-modifying anti-rheumatic drugs were analysed. Remission was assessed using Boolean 1.0, Boolean 2.0, and index-based criteria including DAS in 28 joints calculated with ESR (DAS28-ESR), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Agreement between Boolean definitions and index-based criteria was evaluated using Cohen's kappa. Predictive validity was determined by comparing remission status at week 24 and patient-reported outcomes at week 48, specifically HAQ-Disability Index (HAQ-DI) ≤0.5 and EuroQoL-5 Dimension (EQ-5D) = 1. RESULTS: Among 506 enrolled patients, 414 completed the 48-week follow-up. Boolean 2.0 showed stronger agreement with DAS28-ESR remission than Boolean 1.0 (κ = 0.50 vs. 0.39), but weaker agreement with CDAI (κ = 0.75 vs. 0.48) and SDAI (κ = 0.76 vs. 0.64). Boolean 1.0 demonstrated higher positive predictive values for HAQ-DI ≤0.5 (0.90 vs. 0.82) and EQ-5D = 1 (0.38 vs. 0.30) compared with Boolean 2.0. CONCLUSION: Although Boolean 2.0 improves concordance with DAS28-ESR, it does not enhance the prediction of long-term functional or QoL outcomes. Its broader definition of remission warrants cautious interpretation in clinical practice.
引用
- Cho SK, Choi SR, Nam E, et al. Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy. Rheumatology (Oxford). 2026. PMID: 41025512. doi:10.1093/rheumatology/keaf516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。